Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.
Ellrichmann
Mark
M
Vollmer
Kirsten
K
Schrader
Henning
H
Banasch
Matthias
M
Schmidt
Wolfgang E
WE
Meier
Juris J
JJ
D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000077270:Exenatide; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011994:Recombinant Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012254:Ribavirin / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use*; D019562:Viral Load
D000998:Antiviral Agents; D007004:Hypoglycemic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010455:Peptides; D011994:Recombinant Proteins; D014688:Venoms; D012254:Ribavirin; D000077270:Exenatide